Short Interest in Inhibrx, Inc. (NASDAQ:INBX) Rises By 5.5%

Inhibrx, Inc. (NASDAQ:INBX) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,030,000 shares, an increase of 5.5% from the October 31st total of 976,700 shares. Approximately 10.3% of the shares of the company are short sold. Based on an average daily volume of 91,800 shares, the days-to-cover ratio is presently 11.2 days.

Inhibrx Price Performance

Shares of NASDAQ INBX opened at $15.08 on Tuesday. The business has a 50-day moving average of $15.43 and a 200-day moving average of $16.15. Inhibrx has a 12 month low of $10.80 and a 12 month high of $18.95.

Insider Activity at Inhibrx

In other Inhibrx news, CEO Mark Lappe acquired 9,500 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was bought at an average price of $15.21 per share, with a total value of $144,495.00. Following the completion of the purchase, the chief executive officer now owns 657,048 shares of the company’s stock, valued at approximately $9,993,700.08. This represents a 1.47 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jon Faiz Kayyem bought 69,686 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was acquired at an average price of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the purchase, the director now directly owns 51,093 shares in the company, valued at approximately $727,053.39. The trade was a -374.80 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 145,365 shares of company stock worth $2,165,469.

Hedge Funds Weigh In On Inhibrx

An institutional investor recently raised its position in Inhibrx stock. Price T Rowe Associates Inc. MD boosted its position in Inhibrx, Inc. (NASDAQ:INBX) by 8.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,812 shares of the company’s stock after acquiring an additional 1,112 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Inhibrx were worth $518,000 as of its most recent filing with the Securities & Exchange Commission. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.